Xeris Biopharma Holdings Stock (NASDAQ: XERS) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 8.000 / 2.317M |
Day Range | - - - |
52 Wk Range | 1.260 - 3.260 |
Market Cap | $296.357M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 36 |
Short Interest | - |
Days to Cover | 5.16 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Xeris Biopharma Holdings (NASDAQ: XERS) through any online brokerage.
Other companies in Xeris Biopharma Holdings’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), Third Harmonic Bio (NASDAQ:THRD), Zevra Therapeutics (NASDAQ:ZVRA) and Terns Pharma (NASDAQ:TERN).
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by HC Wainwright & Co. on Thursday, March 7, 2024. The analyst firm set a price target for 6.00 expecting XERS to rise to within 12 months (a possible 184.36% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Xeris Biopharma Holdings (NASDAQ: XERS) is $2.11 last updated March 27, 2024 at 7:50 PM EDT.
There are no upcoming dividends for Xeris Biopharma Holdings.
Xeris Biopharma Holdings’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Xeris Biopharma Holdings.
Xeris Biopharma Holdings is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.